title: The role of aldosterone receptor antagonists in the management of heart failure: an update.
abstract: The aldosterone receptor antagonists (ARAs) spironolactone (Aldactone) and eplerenone (Inspra) have become part of standard medical therapy for heart failure, having shown clinical efficacy in randomized trials in patients with advanced symptomatic systolic heart failure, postinfarction heart failure with cardiac dysfunction, and systolic heart failure with mild symptoms. The benefits include a lower rate of death. Yet to be answered is whether the two drugs are clinically equivalent; another question is whether they may benefit everyone with symptomatic heart failure, including diastolic heart failure.
authors.affiliation: Department of Hospital Medicine, Cleveland Clinic, USA.
authors.forename: Vijaiganesh
authors.initials: V
authors.lastname: Nagarajan
authors.forename: Mohammed
authors.initials: M
authors.lastname: Chamsi-Pasha
authors.forename: W H Wilson
authors.initials: WH
authors.lastname: Tang
mesh_terms: D000077545:Eplerenone; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D000451:Mineralocorticoid Receptor Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D013148:Spironolactone / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D000451:Mineralocorticoid Receptor Antagonists; D013148:Spironolactone; D000077545:Eplerenone